《大行報告》大和料歐舒丹(00973.HK)藉收購可提升2022年及2023年純利各2%及7%
大和發表報告,對於歐舒丹(00973.HK)收購美國護膚品牌Sol de Janeiro約83%股權,預計將即時增加集團的收入和盈利能力,Sol de Janeiro今年收入有望超過1億美元,並實現約21%的EBITDA利潤。該行予
歐舒丹「買入」評級,目標價32元。
該行估計,受惠今次收購,可提升歐舒丹2022年及2023年純利各2%及7%。在未來3至5年,管理層預計Sol de Janeiro的收入將以每年30%至40%的速度增長,並認爲通過規模、渠道組合和實現與集團的協同效應,其EBITDA利潤率有上升空間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.